Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Aisha Shakeel
01.12.23 -- FDA Accepts Stelara Biosimilar BLA For Review
By Aisha Shakeel and Kieran Reals, PA Consulting This article looks at the needs and challenges biotech organizations face during the manufacture of therapies, how they can reduce costs, and how establishing — or not establishing — partnerships with CDMOs can help get their therapies to patients faster.
12.22.22 -- CDMO Partnerships In Early Development Aren't Always The Best Choice
By Aisha Shakeel and Kieran Reals, PA Consulting This article looks at the needs and challenges biotech organizations face during the manufacture of therapies, how they can reduce costs, and how establishing — or not establishing — partnerships with CDMOs can help get their therapies to patients faster.
12.22.22 -- How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing
By Erin Harris, Editor-In-Chief, Cell & Gene In the final part of the series, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio explain how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.
12.14.22 -- Are You Ready For A Recession?
By Louis Garguilo, Chief Editor, Outsourced Pharma CDMOs have facility utilization and operating profits; Biotechs, burn rates and investors; Pharma, budgets and profitability. The state of the economy affects all of us. In the past, we’ve seen outsourcing behaviors change dramatically during economic downturns. Here's part 1 in a series to get you ready for a downturn.
CDMO Partnerships In Early Development Aren’t Always The Best Choice
By Aisha Shakeel and Kieran Reals, PA Consulting Biotechnology companies understand that a quicker journey from R&D to clinical delivery is a key factor in achieving market success. The importance and possibilities of development and manufacturing scale-up speed were demonstrated most recently during the COVID-19 vaccine programs, with 15.4 billion doses manufactured between December 2020 and October 2022, as reported by UNICEF.
CDMO Partnerships In Early Development Aren’t Always The Best Choice Original
By Aisha Shakeel and Kieran Reals, PA Consulting Biotechnology companies understand that a quicker journey from R&D to clinical delivery is a key factor in achieving market success. The importance and possibilities of development and manufacturing scale-up speed were demonstrated most recently during the COVID-19 vaccine programs, with 15.4 billion doses manufactured between December 2020 and October 2022, as reported by UNICEF.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Aisha
Contact Aisha, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack